ESLA
Estrella Immunopharma Inc.
NASDAQ: ESLA · HEALTHCARE · BIOTECHNOLOGY
$1.64
+11.56% today
Updated 2026-04-30
Market cap
$67.41M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.35
Dividend yield
—
52W range
$1 – $3
Volume
0.1M
Estrella Immunopharma Inc. (ESLA) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $-670820.00 | $-1.44M | $-1.04M | $-16.07M | $-7.64M | $-1.79M |
| Capital expenditures | $0.00 | $0.00 | $0.00 | $0.00 | $1.00 | $0.00 |
| Depreciation | — | — | — | — | — | — |
| Stock-based comp | $62873.00 | $129968.00 | $299915.00 | $1.19M | $1.19M | $618974.00 |
| Free cash flow | $-670820.00 | $-1.44M | $-1.04M | $-16.07M | $-7.64M | $-1.79M |
| Investing cash flow | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — |